< Back to Press Release List

Notch Therapeutics Participates as Sponsor and Presenter at ISSCR 2021 Virtual Meeting

— Poster presentation highlights capabilities of Notch platform for generating consistent and scalable therapeutic T cells from renewable stem cell sources —

— Company sponsors ISSCR 2021 Career Panel on June 25 —

VANCOUVER, British Columbia, June 18, 2021— Notch Therapeutics, Inc., a biotechnology company developing renewable, induced pluripotent stem cell (iPSC)-derived cell therapies for cancer, announced today that the company will present data highlighting the capabilities of the company’s proprietary Engineered Thymic Niche (ETN) platform technology for precisely controlled development of homogeneous, universally compatible, stem cell-derived T cell therapies at industrial scale. The data will be presented at the International Society for Stem Cell Research ISSCR 2021 Virtual Meeting taking place June 21–26, 2021.

In addition to the company’s presentation, Notch will sponsor the ISSCR 2021 Career Panel, “How Has the Pandemic Changed the Decision-Making Process Regarding Your Early Career Goals and Outlook” on Friday, June 25, 2021 from 12:00–1:00 pm EDT. The panel discussion will be hosted by the ISSCR Early Career Scientist Committee and moderated by Stephanie Luff, Ph.D., Icahn School of Medicine at Mount Sinai, U.S.

Notch Virtual Presentation

    • Poster #1018001: “Controlled and Scalable T Cell Differentiation from Induced Pluripotent Stem Cell (iPSC)-Derived Blood Progenitor Cells Using the Engineered Thymic Niche Technology”
    • Presenter: Steven Woodside, Ph.D.
    • Summary & Key Findings: Notch’s proprietary Engineering Thymic Niche (ETN) platform provides a robust and controllable bead-based system that uses Notch signaling to drive differentiation of T cells from iPSC cells.

The ISSCR annual meeting is the most comprehensive gathering of scientists in stem cell research and regenerative medicine in the world. For more information about ISSCR 2021 Virtual, visit www.isscr.org/

About Notch Therapeutics (www.notchtx.com)
Notch is developing a pipeline of cellular immunotherapies originating from pluripotent stem cells that are specifically engineered to address the underlying biology of complex disease systems. The company has unlocked the ability for large-quantity production of T cells and other cells from any source of stem cells to bring best-in-class cell therapies for cancer and other immune disorders to thousands of patients. The core of the Notch platform is the Engineered Thymic Niche (ETN), which enables precision control of cell fate during the differentiation and expansion of stem cells in suspension bioreactors without the need for feeder cells or serum. The ETN has the potential to generate immunotherapies with decreased variability, increased potency, and engineered improvements. The technology was invented in the laboratories of Juan-Carlos Zúñiga-Pflücker, Ph.D. at Sunnybrook Research Institute and Peter Zandstra, Ph.D., FRSC at the University of Toronto. Notch was founded by these two institutions, in conjunction with MaRS Innovation (now Toronto Innovation Acceleration Partners) and the Centre for Commercialization of Regenerative Medicine (CCRM), which initially incubated the company.

Contact:
Mary Moynihan
M2Friend Biocommunications
802-951-9600
mary@m2friend.com